Amgen Inc. has recently unveiled significant advancements in their scientific research, highlighting their pioneering work in modular therapeutic design. Drawing inspiration from nature, Amgen is developing innovative treatments such as bispecific T-cell engagers and RNA-directed therapies. These novel approaches aim to understand biological complexity and create therapeutics with unprecedented impact for patients suffering from serious diseases. Additionally, Amgen is leveraging artificial intelligence and machine learning to accelerate drug discovery and development, selecting clinical trial sites and participants more efficiently, and expediting the regulatory review process. By utilizing vast human datasets, Amgen is also gaining genetic insights to develop precision medicines targeted at serious diseases, marking a pivotal moment for practicing precision medicine.